Linklaters advises Theramex (a portfolio company of PAI Partners and Carlyle) on Theramex’s proposed acquisition of Duphaston and Femoston oral menopause drugs from Viatris
Linklaters has advised Theramex (a portfolio company of Carlyle and PAI Partners) on Theramex’s proposed acquisition of certain rights and assets relating to the menopause therapy drugs Femoston and Duphaston from Viatris, Inc., a NASDAQ-listed pharmaceutical company.
Theramex is a global speciality pharmaceutical company, solely committed to women’s health, operating in 80+ countries, with 500+ employees, 20+ products and serving 6m+ patients. The asset purchase will broaden Theramex's product portfolio, which currently focuses on contraceptives, menopause therapies, osteoporosis products and fertility treatments.
Linklaters previously advised PAI Partners and Carlyle on the acquisition of Theramex from CVC Capital Partners in 2022, and has continued to support the business since.
Closing is subject to customary closing conditions including antitrust and foreign direct investment approvals and receipt of certain required consents.
The cross-jurisdictional team, combining multi-practice expertise and deep Healthcare and Life Sciences Sector experience, was led by Corporate partners Daniel Law and Alex Woodward, alongside managing associate Alexander Selig, and associates Kaiya Kim-Saville, Asim Ayub, Tibi Sandu (all London) and Catherine Yuen (New York). Managing associate James Marlow (London) supported on ESG matters. The Commercial (Carve-Out) team was led by partner Marly Didizian, supported by associates Danny Greenland and Rachel Varnam (all London) and the IP team was led by partner Yohan Liyanage, supported by managing associate Stephanie Farrington, and associate Olivia Williams (all London).